VEA
NTLA icon

Virtus ETF Advisers’s Intellia Therapeutics NTLA Stock Holding History

Virtus ETF Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,242
Closed -$61.1K – 663
2024
Q4 		$61.1K Buy
5,242
+1,692
+48% +$26.4K 0.03% 445
2024
Q3 		$73K Buy
3,550
+63
+2% +$1.45K 0.03% 423
2024
Q2 		$78K Buy
3,487
+768
+28% +$18.3K 0.04% 414
2024
Q1 		$74.8K Sell
2,719
-187
-6% -$5.19K 0.04% 401
2023
Q4 		$88.6K Buy
2,906
+714
+33% +$20.5K 0.06% 407
2023
Q3 		$69.3K Sell
2,192
-214
-9% -$8.3K 0.04% 388
2023
Q2 		$98.1K Sell
2,406
-204
-8% -$8.27K 0.06% 395
2023
Q1 		$97.3K Sell
2,610
-1,000
-28% -$39.2K 0.05% 345
2022
Q4 		$126K Buy
3,610
+890
+33% +$42.3K 0.07% 403
2022
Q3 		$152K Buy
2,720
+26
+1% +$1.61K 0.06% 352
2022
Q2 		$139K Buy
2,694
+1,341
+99% +$68.1K 0.05% 331
2022
Q1 		$98K Sell
1,353
-72
-5% -$6.1K 0.04% 306
2021
Q4 		$168K Sell
1,425
-994
-41% -$125K 0.06% 296
2021
Q3 		$325K Sell
2,419
-123
-5% -$18.6K 0.14% 191
2021
Q2 		$412K Sell
2,542
-3,219
-56% -$251K 0.17% 190
2021
Q1 		$462K Buy
5,761
+99
+2% +$6.64K 0.2% 159
2020
Q4 		$308K Sell
5,662
-10,265
-64% -$373K 0.13% 202
2020
Q3 		$317K Sell
15,927
-2,173
-12% -$45.3K 0.17% 208
2020
Q2 		$380K Buy
+18,100
New +$307K 0.18% 219

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtus ETF Advisers's NTLA Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 5,242 shares — an estimated $61.1K sold.

Virtus ETF Advisers first reported a position in NTLA in Q2 2020 and held it in 19 quarters. The position peaked at $462K in Q1 2021. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 5,242 Intellia Therapeutics shares in Q1 2025, an estimated $61.1K.
  • Virtus ETF Advisers first reported a position in Intellia Therapeutics in Q2 2020 and held it in 19 quarters.
  • Virtus ETF Advisers's Intellia Therapeutics position peaked at $462K in Q1 2021.
  • 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.